Skip to main content
. 2018 Jun 22;5(3):165–168. doi: 10.5152/eurjrheum.2018.17163

Table 2.

Characteristics of the patients without a history of concomitant comorbid inflammatory disease

Case ID Age at diagnosis of HS, years Age at diagnosis of IED, years Sex Race Type of IED Laterality Treatment HS stage
1 41 53 Female African-American Iridocyclitis Bilateral Improved II
2 52 59 Female African-American Anterior uveitis Unilateral Topical steroid → remission I
3 49 56 Male African-American Scleritis Unilateral Topical steroid for 3 months → failed → 2 months of 60 mg daily prednisone → remission → topical steroid for 3 years → remission I
4 38 41 Female African-American Scleritis Unilateral Topical steroid for 9 months → failure → 60 mg daily prednisone for 1 year → failure → adalimumab stopped due to financial problem
5 37 33 Female Caucasian Scleritis Unilateral Topical steroid → improved II
6 49 48 Female Caucasian Iritis Unilateral Methotrexate 10–15 weekly → not known Topical steroid → improved
7 51 46 Female Caucasian Panuveitis Bilateral Topical steroid → improved

HS: hidradenitis suppurativa; IED: inflammatory eye disease